Company intelligence / Profile preview

Groupe Papyrus

West Chester, Pennsylvania, United Statesm.facebook.com ↗

Ownership: Private
Development stage: Other

Overview

Papyrus Therapeutics is developing a novel class of tumor suppressor-based biotherapeutic agents, primarily focusing on recombinant OPCML-Fc fusion proteins. Their lead asset, PYTX‑004, has shown strong preclinical efficacy as both monotherapy and combination therapy in ovarian cancer models with no observed adverse toxicities. The company’s approach aims to restore silenced tumor suppressors in various solid tumors, offering a targeted alternative to traditional oncogene-focused therapies.

Therapeutic areas: Oncology
Modalities: Recombinant proteinFusion proteinBiological productsOncolytic virusCAR-T
Industry: Biotech

Partnerships

Oxford BioMedica

Beyond the preview

Go deeper on Groupe Papyrus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Groupe Papyrus.

Explore the full profile